This month’s issue of Going on Trial takes a sneak peek at some early null results from a small trial of a cannabidiol-based drug for autism, among other recent drug developments.
SourceSource: Spectrum News
A careful clinician who prizes evidence, Jeremy Veenstra-VanderWeele is happy to embrace trial failures, as long as he learns from them.
SourceSource: Spectrum News
A potential threat to the integrity of data collected online and an analysis of the structure and function of dopamine receptors caught researchers’ attention on social media this week.
SourceSource: Spectrum News
Autistic people tend to drop out of Medicaid once they reach adulthood in states that don’t waive the income restrictions on enrollment.
SourceSource: Spectrum News
The drug clemastine and other compounds that fortify the protective sheath around neurons may prove therapeutic for some genetic neurodevelopmental conditions.
SourceSource: Spectrum News
These scores — composite measures of a person’s autism-linked common genetic variants — cannot predict an autism diagnosis but could help researchers better understand the condition’s underlying biology.
SourceSource: Spectrum News
This week on social media, scientists discussed a new tool to quantify motion in 3D and responded to the announcement of the launch of Imaging Neuroscience.
SourceSource: Spectrum News
Few studies have tracked how brain structure and function change across adulthood in people with autism. Carper and her colleagues are collecting data to fill this gap.
SourceSource: Spectrum News